Back to today’s briefing

Story perspectives

Big Pharma Teams Up with China's Rising Biotech Power

8/8/2025

50 5

Summary

Story summary

Western pharmaceutical giants are forging powerful alliances with Chinese biotech firms, drawn by cost efficiency and cutting-edge AI technology. AstraZeneca's staggering $5 billion partnership with CSPC and Pfizer's collaboration with XtalPi exemplify this shift. With state backing and a wave of returning talent, China's biotech landscape is rapidly evolving into a formidable force in drug discovery, rivaling U.S. supremacy.

1 of 1

Story summary

Western pharmaceutical giants are forging powerful alliances with Chinese biotech firms, drawn by cost efficiency and cutting-edge AI technology. AstraZeneca's staggering $5 billion partnership with CSPC and Pfizer's collaboration with XtalPi exemplify this shift. With state backing and a wave of returning talent, China's biotech landscape is rapidly evolving into a formidable force in drug discovery, rivaling U.S. supremacy.